ORCID as entered in ROS

Select Publications
2020, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-SY09-02
,2020, 'Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368301146&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Prevalence and Spectrum of Germline Mutations in Children with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S503 - S504, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458005160&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children and Adolescents with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S504 - S505, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458005162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'iPREDICT: Incorporating complex profiling of patients to enrol onto molecularly directed cancer therapeutics. Preliminary results of the adult and paediatric', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 184 - 185, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400299&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Prevalence and spectrum of germline mutations in children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 42 - 43, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with highrisk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 70 - 71, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'DEVELOPMENT OF NEXT GENERATION CAR'S TARGETING THE LEWIS Y ANTIGEN FOR THE TREATMENT OF CANCER', in CYTOTHERAPY, ELSEVIER SCI LTD, Vol. 21, pp. E15 - E15, http://dx.doi.org/10.1016/j.jcyt.2019.04.050
,2019, 'THER-23. RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRATED PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in Neuro-Oncology, Oxford University Press (OUP), Vol. 21, pp. ii118 - ii118, http://dx.doi.org/10.1093/neuonc/noz036.228
,2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111
,2018, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 65, pp. S643 - S644, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445195005221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CO, Denver, Vol. 20, pp. 67 - 67, presented at 18th International Symposium on Pediatric Neuro-Oncology (ISPNO), CO, Denver, 30 June 2018 - 03 July 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000438339000180&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 20, pp. i67 - i67, http://dx.doi.org/10.1093/neuonc/noy059.178
,2018, 'Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-137
,2018, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-138
,2018, 'Zero childhood cancer – Accelerating translation of experimental oncology: Better matching drug to target', in Pathology, Elsevier BV, Vol. 50, pp. S31 - S31, http://dx.doi.org/10.1016/j.pathol.2017.12.072
,2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539
,2025, Systematic silencing of oncogenic fusion transcripts with ultra-precise CRISPR-Cas13b, http://dx.doi.org/10.1101/2025.02.10.637348
,2024, Integrated germline and somatic molecular profiling to detect cancer predisposition has a high clinical impact in poor-prognosis paediatric cancer, http://dx.doi.org/10.1101/2024.08.08.24311493
,2023, Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas, http://dx.doi.org/10.1101/2023.07.19.548825
,2023, Molecular principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision, http://dx.doi.org/10.1101/2023.09.26.557083
,2023, Precision-guided treatment improves outcomes for children with high-risk cancers, http://dx.doi.org/10.21203/rs.3.rs-3376668/v1
,2023, TALLSorts: a T-cell acute lymphoblastic leukaemia subtype classifier using RNA-seq expression data, http://dx.doi.org/10.1101/2023.04.05.535648
,2022, A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer, http://dx.doi.org/10.1101/2022.09.16.508179
,2022, Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions, http://dx.doi.org/10.21203/rs.3.rs-1714034/v1
,2022, Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusions, http://dx.doi.org/10.1101/2022.06.22.497105
,2022, Toblerone: detecting exon deletion events in cancer using RNA-seq, http://dx.doi.org/10.1101/2022.10.27.514132
,2021, Slinker: Visualising novel splicing events in RNA-Seq data, http://dx.doi.org/10.12688/f1000research.74836.1
,Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia, http://dx.doi.org/10.2139/ssrn.3707264
,2025, Zero Childhood Cancer: a national approach to improving outcomes of Australian children with cancer through multiomic precision medicine, Elsevier BV, http://dx.doi.org/10.1016/j.pathol.2024.12.099
,2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498
,2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v3
,2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213.v1
,2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000210.v1
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000210
,2023, Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000207.v1
,2023, Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000207
,2023, Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000204.v1
,2023, Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000204
,2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v2
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23952251
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23952251.v1
,2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v1
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23808560.v1
,2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23808560
,